{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:28:28Z","timestamp":1790724508443,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10096-025-05235-0","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T12:44:15Z","timestamp":1755521055000},"page":"2771-2778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Eravacycline: evaluation of susceptibility testing methods and activity against multidrug-resistant Enterobacterales and Acinetobacter"],"prefix":"10.1007","volume":"44","author":[{"given":"Am\u00e9lie","family":"Kinet-Poleur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bogaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Din","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"5235_CR1","unstructured":"World Health Organization (WHO) (2024) Bacterial Priority Pathogens List: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance"},{"key":"5235_CR2","doi-asserted-by":"publisher","unstructured":"Talsma Ditmer T et al (2024) Nosocomial transmission of tet(x3), blaNDM-1 and blaOXA-97-carrying Acinetobacter baumannii conferring resistance to eravacycline and omadacycline, the Netherlands, March to August 2021. Euro Surveillance\u00a029(28): 2400019. Available at: https:\/\/doi.org\/10.2807\/1560-7917","DOI":"10.2807\/1560-7917"},{"key":"5235_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jgar.2024.03.014","volume":"37","author":"M-H Tsai","year":"2024","unstructured":"Tsai M-H et al (2024) Antimicrobial activity of Eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in taiwan: A clinical Microbiological study. J Global Antimicrob Resist 37:93\u201399. https:\/\/doi.org\/10.1016\/j.jgar.2024.03.014","journal-title":"J Global Antimicrob Resist"},{"issue":"7","key":"5235_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/biom14070783","volume":"14","author":"D Kounatidis","year":"2024","unstructured":"Kounatidis D et al (2024) Third-generation tetracyclines: current knowledge and therapeutic potential. Biomolecules 14(7):783. https:\/\/doi.org\/10.3390\/biom14070783","journal-title":"Biomolecules"},{"issue":"5","key":"5235_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG et al (2016) Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 76(5):567\u2013588","journal-title":"Drugs"},{"key":"5235_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02351-23","author":"AJ Kunz Coyne","year":"2024","unstructured":"Kunz Coyne AJ et al (2024) Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. https:\/\/doi.org\/10.1128\/spectrum.02351-23","journal-title":"Microbiol Spectr"},{"issue":"9","key":"5235_CR7","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1093\/jac\/dkae220","volume":"79","author":"R Jing","year":"2024","unstructured":"Jing R et al (2024) Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus. J Antimicrob Chemother 79(9):2246\u20132250. https:\/\/doi.org\/10.1093\/jac\/dkae220","journal-title":"J Antimicrob Chemother"},{"key":"5235_CR8","unstructured":"Latour K (2018) Surveillance of antimicrobial resistant bacteria in Belgian hospitals. Sciensano Report"},{"key":"5235_CR9","unstructured":"Denis O, Huang T-D (2024) Epidemiology of resistance in gram negative bacteria. Formation donn\u00e9e dans le cadre du certificat inter-universitaire d\u2019infectiologie et microbiologie clinique, 18 janvier"},{"key":"5235_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1496402","author":"JJ Liu","year":"2024","unstructured":"Liu JJ et al (2024) Efficacy and safety of Eravacycline versus Tigecycline for complicated intra-abdominal infections in the ICU: a multicenter, single-blind, parallel randomized controlled trial study protocol. Front Med. https:\/\/doi.org\/10.3389\/fmed.2024.1496402","journal-title":"Front Med"},{"key":"5235_CR11","first-page":"210","volume":"45","author":"G Meletis","year":"2022","unstructured":"Meletis G et al (2022) In vitro activity of Eravacycline and cefoperazone\/sulbactam against extensively-drug resistant and pan-drug resistant Acinetobacter baumannii isolates from a tertiary hospital in Greece. New Microbiol 45:210\u2013212","journal-title":"New Microbiol"},{"key":"5235_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1356353","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024) Emergence of Eravacycline heteroresistance in carbapenem-resistant Acinetobacter baumannii isolates in China. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/fcimb.2024.1356353","journal-title":"Front Cell Infect Microbiol"},{"key":"5235_CR13","doi-asserted-by":"publisher","first-page":"100565","DOI":"10.1016\/j.ijmmb.2024.100565","volume":"48","author":"H Gautam","year":"2024","unstructured":"Gautam H et al (2024) Antimicrobial efficacy of Eravacycline against emerging extensively drug-resistant (XDR) acinetobacter baumannii isolates. Ind J Med Microbiol 48:100565. https:\/\/doi.org\/10.1016\/j.ijmmb.2024.100565","journal-title":"Ind J Med Microbiol"},{"issue":"2","key":"5235_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/jbcr\/irad183","volume":"45","author":"C Alexander","year":"2023","unstructured":"Alexander C, Hill D (2023) A retrospective case-control study of Eravacycline for the treatment of carbapenem-resistant Acinetobacter infections in patients with burn injuries. J Burn Care Res 45(2):487\u2013492. https:\/\/doi.org\/10.1093\/jbcr\/irad183","journal-title":"J Burn Care Res"},{"key":"5235_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117666","volume":"181","author":"P Garc\u00eda","year":"2024","unstructured":"Garc\u00eda P et al (2024) Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii. Biomed Pharmacother 181:117666. https:\/\/doi.org\/10.1016\/j.biopha.2024.117666","journal-title":"Biomed Pharmacother"},{"key":"5235_CR16","doi-asserted-by":"publisher","first-page":"e01390","DOI":"10.1128\/spectrum.01390-22","volume":"10","author":"C Xu","year":"2022","unstructured":"Xu C et al (2022) Development of resistance to eravacycline by Klebsiella pneumoniae and collateral sensitivity-guided design of combination therapies. Microbiol Spectr 10:e01390\u2013e01322. https:\/\/doi.org\/10.1128\/spectrum.01390-22","journal-title":"Microbiol Spectr"},{"issue":"3","key":"5235_CR17","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/aac.04809-14","volume":"59","author":"M Abdallah","year":"2015","unstructured":"Abdallah M et al (2015) Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 59(3):1802\u20131805. https:\/\/doi.org\/10.1128\/aac.04809-14","journal-title":"Antimicrob Agents Chemother"},{"key":"5235_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01715-19","author":"I Morrissey","year":"2020","unstructured":"Morrissey I et al (2020) In vitro activity of eravacycline against gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01715-19","journal-title":"Antimicrob Agents Chemother"},{"key":"5235_CR19","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s12879-019-4093-1","volume":"19","author":"C Zhao","year":"2019","unstructured":"Zhao C et al (2019) In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China. BMC Infect Dis 19:508. https:\/\/doi.org\/10.1186\/s12879-019-4093-1","journal-title":"BMC Infect Dis"},{"key":"5235_CR20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","volume":"33","author":"S Hawser","year":"2023","unstructured":"Hawser S et al (2023) In vitro activity of Eravacycline and comparators against gram-negative and gram-positive bacterial isolates collected from patients globally between 2017 and 2020. J Global Antimicrob Resist 33:304\u2013320. https:\/\/doi.org\/10.1016\/j.jgar.2023.04.017","journal-title":"J Global Antimicrob Resist"},{"key":"5235_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01650-22","author":"LS Blanchard","year":"2023","unstructured":"Blanchard LS et al (2023) Multicenter clinical evaluation of etest Eravacycline for susceptibility testing of Enterobacteriaceae and enterococci. J Clin Microbiol. https:\/\/doi.org\/10.1128\/jcm.01650-22","journal-title":"J Clin Microbiol"},{"issue":"2","key":"5235_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/jac\/dkae426","volume":"80","author":"Q Liu","year":"2024","unstructured":"Liu Q et al (2024) Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, mic test strip and disc diffusion. J Antimicrob Chemother 80(2):439\u2013444. https:\/\/doi.org\/10.1093\/jac\/dkae426","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"5235_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060866","volume":"8","author":"SH Lan","year":"2019","unstructured":"Lan SH et al (2019) The efficacy and safety of eravacycline in the treatment of complicated intra-abdominal infections: a systemic review and meta-analysis of randomized controlled trials. J Clin Med 8(6):866. https:\/\/doi.org\/10.3390\/jcm8060866","journal-title":"J Clin Med"},{"issue":"4","key":"5235_CR24","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1128\/AAC.01614-13","volume":"58","author":"JS Solomkin","year":"2014","unstructured":"Solomkin JS et al (2014) Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of Eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother 58:1847\u20131854. https:\/\/doi.org\/10.1128\/AAC.01614-13","journal-title":"Antimicrob Agents Chemother"},{"key":"5235_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"Solomkin J et al (2017) 'Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial\u2019. JAMA Surg. 152:224\u201332. https:\/\/doi.org\/10.1001\/jamasurg.2016.4237","journal-title":"JAMA Surg."},{"key":"5235_CR26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jgar.2021.02.009","volume":"24","author":"K Eljaaly","year":"2021","unstructured":"Eljaaly K et al (2021) Efficacy and safety of eravacycline: A meta-analysis. J Global Antimicrob Resist 24:424\u2013428. https:\/\/doi.org\/10.1016\/j.jgar.2021.02.009","journal-title":"J Global Antimicrob Resist"},{"key":"5235_CR27","doi-asserted-by":"publisher","first-page":"p935343","DOI":"10.3389\/fmed.2022.935343","volume":"9","author":"R Meng","year":"2022","unstructured":"Meng R et al (2022) The efficacy and safety of Eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A bayesian network meta-analysis. Front Med 9:p935343. https:\/\/doi.org\/10.3389\/fmed.2022.935343","journal-title":"Front Med"},{"issue":"5","key":"5235_CR28","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jiph.2024.03.027","volume":"17","author":"Y-S Huang","year":"2024","unstructured":"Huang Y-S et al (2024) Evaluation of the synergistic effect of Eravacycline and Tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae. J Infect Public Health 17(5):929\u2013937. https:\/\/doi.org\/10.1016\/j.jiph.2024.03.027","journal-title":"J Infect Public Health"},{"issue":"3","key":"5235_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2023.116006","volume":"107","author":"R Rahul","year":"2023","unstructured":"Rahul R et al (2023) Eravacycline -synergistic activity with other antimicrobials in carbapenem resistant isolates of Escherichia coli and Acinetobacter baumannii. Diagn Microbiol Infect Dis 107(3):116006. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2023.116006","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05235-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05235-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05235-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T12:35:57Z","timestamp":1763210157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05235-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["5235"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05235-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}